SynDevRx Chief Business Officer Jim Shanahan lists the rationale behind selecting evexomostat as the company’s lead candidate.
#SyntheticBiology #DrugDiscovery #LifeSciences #BiotechInnovation #BiotechInvestor #HealthcareInvesting #VentureCapital #BioTechStartup #HealthTech #MedTech #BioPharma
0
0
0
0